Malaria Vaccine (R21/Matrix-M)

R21/Matrix-M is a malaria vaccine developed by the University of Oxford and Serum Institute of India. WHO recommended RTS,S in 2021; R21 shows higher efficacy. First vaccine to significantly reduce malaria in children.

The Malaria Vaccine (R21/Matrix-M) is recommended for 5–36 months (children in endemic areas). It falls under the Travel vaccine category. Consult your doctor to confirm if this vaccine is right for you based on your health history and existing immunity.

The Malaria Vaccine (R21/Matrix-M) has an efficacy of 75–80% efficacy in seasonal malaria prevention. This means it provides significant protection against Plasmodium falciparum malaria. Efficacy may vary based on age, health status, and the specific strain encountered.

Common side effects include: Injection site pain; fever; irritability; drowsiness.. These are typically mild and resolve within 1–3 days. Serious allergic reactions are rare — if you experience difficulty breathing, hives, or rapid heartbeat after vaccination, seek emergency care immediately.

The Malaria Vaccine (R21/Matrix-M) should be avoided by: Hypersensitivity to vaccine components. Not yet recommended for non-endemic travelers.. Always inform your healthcare provider of your full medical history before vaccination.

The Malaria Vaccine (R21/Matrix-M) typically costs Pricing being established for endemic countries in India. Government health centres may offer it free or at subsidised prices for eligible age groups. Private hospitals and clinics may charge differently. Additional fees may apply for administration.